- XMeNa patent granted in
Australia . - Water Soluble patent granted in
Brazil - Tax-dox-mix notice of allowance for the patent in
Brazil .
Uppsala, Sweden, December 29, 2020 –
XMeNa platform patent granted in
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17™, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea® (paclitaxel micellar), which is being launched in key markets globally.
“Water Soluble” patent granted in
The newly approved “Water soluble” patent is related to a novel nanoparticular formulation of a water soluble pharmaceutically active substances, such as doxorubicin, in combination with Oasmia’s patented technology XR-17. Doxorubicin is used to treat a variety of different forms of cancer such as acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, amongst others.
The patent is also related to the product candidate Doxophos Vet® which Oasmia developed for the treatment of lymphoma, the most common cancer in dogs.
“Tax-dox-mix” patent receives notice of allowance in
The tax-dox-mix patent is related to the Oasmia project
For more information:
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the
© Modular Finance, source